Status and phase
Conditions
Treatments
About
The objectives are to demonstrate that entecavir has antiviral activity undetectable HBV DNA measured, the Roche AmplicorTM PCR at Week 48, and to assess the safety and the pharmacokinetic of entecavir in Japanese patients with hepatitis B who have an incomplete response to current lamivudine therapy
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Documentation of chronic hepatitis B infection by ALL of the following:
ALT in the range of 1.3 to 10 x ULN
Subjects must have well-compensated liver disease a) value
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
84 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal